197 related articles for article (PubMed ID: 24987188)
1. Differential ammonia decay kinetics indicates more than one concurrent etiological mechanism for symptomatic hyperammonemia caused by valproate overdose.
Mojumder DK; De Oleo RR
Indian J Pharmacol; 2014; 46(3):345-7. PubMed ID: 24987188
[TBL] [Abstract][Full Text] [Related]
2. Gait instability in valproate-treated patients: Call to measure ammonia levels.
Kipervasser S; Elger CE; Korczyn AD; Nass RD; Quesada CM; Neufeld MY
Acta Neurol Scand; 2017 Nov; 136(5):401-406. PubMed ID: 28436001
[TBL] [Abstract][Full Text] [Related]
3. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
Hamed SA; Abdella MM
Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
[TBL] [Abstract][Full Text] [Related]
4. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
[TBL] [Abstract][Full Text] [Related]
5. Hyperammonemia following intravenous valproate loading.
DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
[TBL] [Abstract][Full Text] [Related]
6. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
[TBL] [Abstract][Full Text] [Related]
7. Influence of valproate-induced hyperammonemia on treatment decision in an adult status epilepticus cohort.
Habhab SF; Ulvin LB; Taubøll E; Svalheim S; Olsen KB; Horn MA; Heuser K
Epilepsy Behav; 2020 Oct; 111():107193. PubMed ID: 32759060
[TBL] [Abstract][Full Text] [Related]
8. Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid.
Smith KM; Britton JW; Hocker SE; Toledano M
Neurologist; 2021 May; 26(3):80-82. PubMed ID: 33942787
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
Kwack DW; Kim DW
Clin Neurol Neurosurg; 2023 Oct; 233():107962. PubMed ID: 37717359
[TBL] [Abstract][Full Text] [Related]
10. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation.
Schiavo A; Maldonado C; Vázquez M; Fagiolino P; Trocóniz IF; Ibarra M
Eur J Pharm Sci; 2023 Apr; 183():106399. PubMed ID: 36740101
[TBL] [Abstract][Full Text] [Related]
11. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
[TBL] [Abstract][Full Text] [Related]
12. [Hyperammonemia in valproate therapy in children and adolescents].
Laub MC
Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
[TBL] [Abstract][Full Text] [Related]
13. Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder.
Yokoyama S; Yasui-Furukori N; Nakagami T; Miyazaki K; Ishioka M; Tarakita N; Kubo K; Sugawara N; Shimoda K
Ther Drug Monit; 2020 Oct; 42(5):766-770. PubMed ID: 32482992
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid-induced hyperammonemia: a case report.
McCall M; Bourgeois JA
J Clin Psychopharmacol; 2004 Oct; 24(5):521-6. PubMed ID: 15349008
[TBL] [Abstract][Full Text] [Related]
15. Valproic Acid-Associated Hyperammonemia: A Systematic Review.
Wong YJ; Fan J; Wan A; Mihic T; Gnyra M
J Clin Psychopharmacol; 2023 May-Jun 01; 43(3):283-294. PubMed ID: 37126830
[TBL] [Abstract][Full Text] [Related]
16. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
Larsen EP; Ostergaard JR
Seizure; 2014 Jun; 23(6):429-34. PubMed ID: 24647346
[TBL] [Abstract][Full Text] [Related]
17. Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy.
Barrueto F; Hack JB
Acad Emerg Med; 2001 Oct; 8(10):999-1001. PubMed ID: 11581089
[TBL] [Abstract][Full Text] [Related]
18. [The decreased level of plasma carnitine in patients with epilepsy].
Belousova ED
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):106-110. PubMed ID: 28745680
[TBL] [Abstract][Full Text] [Related]
19. Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: A case series and literature review.
Brown LM; Cupples N; Moore TA
Ment Health Clin; 2018 May; 8(3):148-154. PubMed ID: 29955560
[TBL] [Abstract][Full Text] [Related]
20. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
